An OncLive Scientific Interchange and Workshop covered sequencing, toxicity management, and access barriers for CAR T-cell therapy in multiple myeloma.
News|Videos|July 8, 2024
Zanubrutinib vs. Acalabrutinib in B-Cell Malignancies: An Adverse Event-Based Economic Analysis
Author(s)Talha Munir, MBChB, PhD
An economic analysis of Zanubrutinib versus Acalabrutinib and associated QoL benefits in AE management in patients with B-cell malignancies.
Advertisement
Advertisement
Related to this article
Roswell Park researchers showed that blocking a novel metabolic pathway severely restricts tumor proliferation.
Dostarlimab monotherapy met the primary end point of sustained clinical complete response at 12 months in the phase 2 AZUR-1 trial.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
The decision does not reflect new concerns about the clinical efficacy or safety data from the phase 3 CARES-310 trial.
The FDA accepted a new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed/refractory multiple myeloma.
Mark Garzotto, MD, discusses data with aglatimagene besadenovec plus valacyclovir and EBRT in intermediate- to high-risk localized prostate cancer.
Rocbrutinib elicited an overall response rate of 63.9% in covalent BTK inhibitor–pretreated relapsed/refractory mantle cell lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Mezigdomide Plus Kd in R/R Myeloma
2
Dostarlimab Achieves Sustained Clinical Complete Responses in dMMR/MSI-H Rectal Cancer
3
Access, Sequencing Considerations Remain Key Focal Points for CAR T-Cell Therapy in R/R Myeloma
4
Dive Into Key Data and Presentations From EHA 2026
5